1Hna SL, lee HC, Yu CW, et al. Value of procaleitonin in differentiating pulmonary tuberculosis from other pulmonary infections: a meta- analysis[J]. Int J Tuberc Lung Dis, 2014, 18(4) : 470-477.
2Espafia PP, Capelastegui A, Bilbao A, et al. Utility of two biomarkers for directing care among patients with non-severe community- acquired pneumonia[ J]. Eur J Clin Microbiol Infect Dis, 2012, 31 (12) : 3397-3405.
3Johansson N, Kalin M, Backman-Johansson C, et al. Proealcitonin levels in community-acquired pneumonia-correlationwith aetiology and severity[J]. Scand J Infect Dis, 2014, 46( 11 ) : 787-791.
4Niu WY, Wan YG, Li MY, et al. The diagnostic value of serum pmcalcitonin, IL-10 and C-reactive protein in community acquired pneumonia and tuberculosi[ J]. Eur Rev Med Pharmacol Sci, 2013, 17(24) : 3329-3333.
5Bello S, Minchol6 E, Fandos S, et al. Inflammatory response in mixed viral-bacterial community-acquired pneumonia [ J ]. BMC Pulm Med, 2014 , 14: 123.
6Tamura M, Watanabe M, Nakajima A, et al. Serial quantification of procalcitonin (PCT) predicts clinical outcome and prognosis in patients with community-acquired pneumonia (CAP) [ J ]. J Infect Chemother, 2014, 20(2): 97-103.
7Andrijevic I, Matijasevic J, Andrijevic L, et al. Interleukin-6 and procalcitonin as biomarkers in mortality prediction of hospitalized patients with community acquired pneumonia[ J]. Ann Thorac Med,2014, 9(3) : 162-167.
8Sahin 17, Yazar E, Yildiz P. Prominent features of platelet count, plateleterit,mean platelet volume and platelet distribution width in pulmonary tuberculosis [ J ]. Muhidiseip Respir Med, 2012, 7 ( 1 ) : 38.
9Moret I, Lorenzo M J, Sarria B, et al. Increased lung neutrophil apoptosis and inflammation resolution in nonresponding pneumonia [J]. Eur Respir J, 2011,38(5) : 1158-1164.
10Dorj G, Hendrie D, Parsons RW, et al. A questionnaire study of injections prescribed and dispensed for patients diagnosed with mild/ moderate community-acquired pneumonia in Mongolia [ J]. Peer J, 2015, 3: e1375.
